

11/15/01

11003 U.S. PTO

12-05-01

A

**UTILITY
PATENT APPLICATION
TRANSMITTAL**(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No.: D/A1505

Total Pages:

First Named Inventor or Application Identifier

Thomas W. Smith et al.

Express Mail Label No.: EL 730901665

11003 U.S. PTO
10/001572

11/15/01

APPLICATION ELEMENTSSee MPEP Chapter 600 concerning
utility patent application contents.

ADDRESS TO:

**Commissioner for Patents
Box Patent Application
Washington, DC 20231**

- 1.
- ☒
- Fee Transmittal Form
-
- (Submit an original, and a duplicate for fee processing)

- 2.
- ☒
- Specification (incl. claims) (Total Pages: 103)

- 3.
- ☐
- Drawing(s) (35 USC 113) (Total Sheets:)

☐ Informal ☐ Formal

Use Figure for front page of Publication.

- 4.
- ☒
- Oath or Declaration (Total Pages: 2)

- a.
- ☒
- Newly executed
-
- (original or copy)

- b.
- ☐
- Copy from a prior application (37 CFR 1.63(d))
-
- (for continuation/divisional with Box 17 completed)
-
- (Note Box 5 below)

- ☐
- i.
- DELETION OF INVENTOR(S)**
-
- Signed statement attached deleting
-
- inventor(s) named in the prior application,
-
- see 37 CFR 1.63(d)(2) and 1.33(b).

- 5.
- ☐
- Incorporation By Reference
-
- (usable if Box 4b is checked)
-
- The entire disclosure of the prior application, from
-
- which a copy of the oath or declaration is supplied
-
- under Box 4b, is considered as being part of the
-
- disclosure of the accompanying application and is
-
- hereby incorporated by reference therein.

- 6.
- ☐
- Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
-
- (If applicable, all necessary)

- a.
- ☐
- Computer Readable Copy
-
- b.
- ☐
- Paper Copy (Identical to computer copy)
-
- c.
- ☐
- Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8.
- ☒
- Assignment Papers (cover sheet & document(s))

- 9.
- ☐
- 37 CFR 3.73(b) Statement
- ☒
- Power of Attorney
-
- (when there is an assignee)

- 10.
- ☐
- English Translation Document (if applicable)

- 11.
- ☒
- Information Disclosure
-
- Statement (IDS)/PTO-1449
- ☒
- Copies of IDS
-
- Citations

- 12.
- ☐
- Preliminary Amendment

- 13.
- ☒
- Return Receipt Postcard (MPEP 503)
-
- (Should be specifically itemized)

- 14.
- ☐
- Small Entity
- ☐
- Statement filed in prior application,
-
- Statement(s) Status still proper and desired

- 15.
- ☐
- Certified Copy of Priority Document(s)
-
- (If foreign priority is claimed)

- 16.
- ☐
- Other:

- 17.
- ☐
- If a
- CONTINUING APPLICATION**
- , check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: /**18. CORRESPONDENCE ADDRESS**☐ Same as prior application☒ Correspondence address below

NAME Patent Documentation Center

ADDRESS Xerox Corporation, 100 Clinton Ave. S., Xerox Square 20th Floor

CITY Rochester

STATE

NY

ZIP CODE

14644

COUNTRY U.S.A.

TELEPHONE

716-423-4564

FAX

716-423-5240 or
716-423-6059

UTILITY PATENT APPLICATION TRANSMITTAL - 37 CFR 1.53(b)
(Executed Attachment to Page 1)

Page 2

Attorney Docket No. D/A1505

19. ☐ Cancel in this application original claims: _____ of the prior application before calculating the filing fee.
(At least one original independent claim is retained for this filing).

20. ☒ The filing fee is calculated below:


CLAIMS AS FILED, LESS ANY CLAIMS CANCELED BY ABOVE-INDICATED AMENDMENT(S)				
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
TOTAL CLAIMS (37 CFR 1.16(c))	20 - 20 =	0	X \$ 18	= \$0.00
INDEPENDENT CLAIMS (37 CFR 1.16(b))	2 - 3 =	0	X \$ 84	= \$0.00
MULTIPLE DEPENDENT CLAIMS (IF APPLICABLE) (37 CFR 1.16(d))		ANY -- 0	\$ 280	= \$0.00
BASIC FEE (37 CFR 1.16(a))				\$740.00
TOTAL				= \$ 740.00

21. ☒ The Commissioner is hereby authorized to charge any filing or prosecution fees which may be required, under 37 CFR 1.16, 1.17, and 1.21 (but not 1.18), or to credit any overpayment, to Account No. 24-0025.
An additional copy of this form is enclosed.
22. ☒ This is an authorization under 37 CFR 1.136(a)(3) to treat any concurrent or future reply, requiring a petition for extension of time, as incorporating a petition for the appropriate extension of time.
23. ☐ Amend the specification by inserting before the first line the sentence:
--This application is a ☐ continuation ☐ continuation-in-part ☐ divisional
of Application(s) No(s). _____, filed _____.--
24. ☐ A CIP declaration is enclosed.
25. ☒ Power of Attorney
- a. ☐ The power of attorney appears in the original papers of the enclosed prior application.
- b. ☐ Enclosed is a copy of the declaration and power of attorney from the enclosed prior application.
- c. ☒ A new declaration with power of attorney is enclosed.

Attorney Docket No.: D/A1505

26. ☐ The following inventors named in the prior application are deleted per 37 CFR 1.53(b)(1), 1.63(d)(2) and 1.33 (b):
27. ☐ This application is adding one or more inventors under 37 CFR 1.48 to a previously executed application, with an enclosed: petition, fee, newly executed declaration from all inventors, and written consent of the assignee.
28. ☐ This application claims the priority benefit of one or more Provisional Application No(s). and the first sentence of this application has been or will be amended to so indicate.
29. ☐ Priority is claimed from
(reinsert all previous priority claims for the entire chain of any prior applications).
30. ☐ This application is NOT to be published under 35 U.S.C. 122(b). The undersigned attorney or agent hereby certifies pursuant to 37 CFR §1.213, that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.
31. ☒ The assignee of this application to be indicated on its publication is Xerox Corporation.
32. ☐ Other paper(s) enclosed:

Respectfully submitted,


Judith L. Byorick
Signature per 37 CFR 1.33 & 34
Date: 11/15/2001
Registration No. 32,606
Telephone No. 716-423-4564

(585)